The Parkinson’s disease diagnosis and treatment market size is estimated to grow from USD 6.32 billion in 2023 to reach around USD 14.36 billion by 2032, registering at a 8.9% of CAGR between 2024 and 2032.
Download a sample of this report @ https://www.towardshealthcare.com/download-statistics/5142
Report Highlights:
- Medications exhibited the contribution to the market with a 40% market share in 2023.
- North America dominated with a 38% market share in 2023.
- Asia Pacific is projected to be the fastest-growing market with a 7.0% CAGR over the forecast period.
According to Parkinson’s News Today, about 41 out of every 100,000 people in their 40s are affected by Parkinson’s disease. This number increases to more than 1,900 out of every 100,000 for people in their 80s and 90s. Parkinson’s is the second most common neurodegenerative disorder, after Alzheimer’s disease. Right now, there’s no cure for Parkinson’s, and people with the condition need lifelong medication support.
Parkinson’s disease is a neurological disorder characterized by involuntary movements such as tremors, stiffness, and difficulty with coordination. Symptoms usually develop gradually and worsen over time, affecting mobility, speech, and cognition. While the exact cause is unclear, research suggests a combination of genetic and environmental factors may contribute to the disease’s onset. Parkinson’s primarily affects the basal ganglia in the brain, leading to a decrease in dopamine production and subsequent movement problems. Despite ongoing research, the exact reasons for nerve cell death in Parkinson’s remain unknown.
Parkinson’s has four major symptoms:
- Tremors in the arms, legs, jaw or hands, head
- Muscle stiffness
- The slow movement
- Diminished balance and coordination, can lead to falls
Parkinson’s Disease Progression Can Be Defined in Stages
There is a lot of interest in finding a treatment that will help slow the progression of Parkinson’s disease. These are known as neuroprotective or disease-modifying drugs. The idea is based on the notion that dopamine-producing neurons can be protected from premature death and dopamine depletion.
At this point, no treatment is neuroprotective. Numerous treatments have been investigated, including MAO-B inhibitors, dopamine agonists, coenzyme Q10, and vitamin E. There is insufficient evidence to conclude that these therapies are beneficial, and they are not currently recommended to slow the Parkinson’s disease. Several clinical trials are being conducted to identify disease-modifying drugs.
- In March 2022, Neuron23 secured $100 million in funding to further develop a therapy for Parkinson’s disease. The company plans to begin trials of NEU-723, a potential treatment for Parkinson’s, by the end of this year.
- Based on a research study, the direct yearly medical expenses for each Parkinson’s disease patient in the U.S. are estimated to range from $10,043 to $12,491. Among these costs, prescription medications make up about 14-22%. Thanks to beneficial healthcare policies and reimbursement systems in developed nations like the U.S., the overall financial strain on individual patients has lessened.
It’s really important to find out if someone has Parkinson’s early and give them the right treatment. This can help them manage their symptoms better and have a better quality of life.
The Occurrence of Parkinson’s Disease is on the Rise Globally
Parkinson’s disease (PD) is a condition that affects the brain and causes problems with movement, like shaking, stiffness, and slow movements. It’s becoming more common worldwide, especially in places where people are living longer lives. As more people get older, the number of those diagnosed with PD goes up.
For instance,
- According to a UN report, in 2020, there were around 727 million people who were 65 years old or older worldwide. This number is expected to double by 2050, reaching over 1.5 billion globally. As the number of older people increases, so does the prevalence of Parkinson’s disease.
- Close to one million individuals in the United States are currently diagnosed with Parkinson’s disease (PD). Projections suggest that this figure will increase to 1.2 million by the year 2030. Parkinson’s stands as the second most prevalent neurodegenerative condition in the country, following Alzheimer’s disease.
- Parkinson’s disease becomes more common as people get older, but about four percent of those diagnosed with PD are under 50 years old.
- Men are 1.5 times more likely to have Parkinson’s disease compared to women.
With more people getting Parkinson’s, there’s a bigger need for tools to help doctors find out if someone has it. These tools include things like scans and tests that can see inside the brain to spot signs of PD. When PD is detected early, doctors can start treatment sooner, which can help manage symptoms better and improve quality of life.
Alongside diagnosis, there’s also a growing demand for treatments. Medicines that help control PD symptoms are becoming more important. These drugs can help reduce shaking, stiffness, and other issues caused by Parkinson’s, allowing people to live more comfortably.
But it’s not just about medicines. As Parkinson’s progresses, people often need additional support. This includes therapies like physical therapy to keep muscles strong and occupational therapy to assist with everyday tasks. With more attention on Parkinson’s disease, there’s also more focus on research. Scientists are working hard to understand the disease better and develop new treatments. This research leads to discoveries that can improve the lives of those with PD.
Deep Brain Stimulation Can Help Tremors and Make Movements Better for Individuals with Parkinson’s Disease
Advancements in medical technology, such as deep brain stimulation (DBS) and infusion therapies, are aiding individuals with Parkinson’s disease (PD) by offering innovative treatment options. Deep brain stimulation involves implanting tiny electric wires in the brain to manage PD symptoms, while infusion therapies deliver medication directly into the body. These advancements contribute to improving patient care. The total cost of Parkinson’s disease in the United States, covering treatment expenses, social security aid, and lost income, is estimated to be around $52 billion annually.
These innovations are a big deal because they expand the choices for treating PD. Before, there weren’t as many options, but now doctors and patients have more to choose from. This means better outcomes for patients – their symptoms can be managed more effectively, helping them feel better and live more comfortably.
For instance,
- DBS can reduce tremors and improve movement for people with PD. It’s like turning down the volume on the symptoms.
And infusion therapies can provide a steady flow of medication, ensuring that patients get the right amount at the right time. Because these treatments work so well, more people want them. This creates a bigger market for companies that make these devices and therapies. They can sell more products, which means they can invest more in research and make even better treatments in the future.
New Treatments Offer More Ways to Manage Parkinson’s Symptoms and Improve Quality of Life
A study supported by the Parkinson’s Foundation in 2022 found that around 90,000 individuals receive a diagnosis of Parkinson’s disease in the United States every year. This marks a significant 50% rise from the earlier estimated figure of 60,000 diagnoses per year. Advancements in treating Parkinson’s disease (PD) are making a big impact on the market for PD diagnosis and treatment. Imagine you have a toolbox, and every time you find a new tool that works better, more people want to use it. That’s what’s happening with PD treatments. Infusion therapy, which delivers medicine directly into the body. These treatments offer new options for managing PD symptoms and improving quality of life.
- In December 2021, a study involving 500 patients found that monoamine oxidase type B (MAO-B) inhibitors were more effective than catechol-O-methyltransferase (COMT) inhibitors in treating Parkinson’s symptoms that were not adequately controlled by levodopa.
- The American Parkinson’s Disease Association (APDA) says there are four FDA-approved medicines called Dopamine Agonists for treating Parkinson’s disease in the U.S. These are Requip (ropinirole), Mirapex (pramipexole), Apokyn (apomorphine), and Neupro (rotigotine). Ropinirole and Pramipexole come in both long-acting and regular forms. Apomorphine is given through a vein injection and works quickly within 10 minutes in emergencies. So, if new medicines get approved for treating Parkinson’s, it will also help this group of medicines to grow.
As more effective treatments become available, more people are seeking help. This increased demand for treatment options is driving growth in the PD market. Companies that make these treatments can sell more products and invest more in research to make even better treatments in the future.
But it’s not just about treatments – better diagnosis tools are also making a difference. When doctors can identify PD earlier, they can start treatment sooner, which can slow down the progression of the disease and improve outcomes for patients.
Difficulty in Early Diagnosis
Diagnosing Parkinson’s disease early on can be tough because its symptoms aren’t always obvious and can resemble those of other health problems. Sometimes, individuals may not even realize they have Parkinson’s because the signs are subtle. This makes it hard for doctors to identify the disease quickly and start the right treatment. It’s like trying to find the right answer in a big book with lots of similar-looking pages – you need time to carefully examine each one to find the correct information. Similarly, doctors need time and specific tests to carefully study the symptoms and confirm if it’s Parkinson’s. Getting an early diagnosis is important because it lets doctors begin treatment sooner. Starting treatment early can help manage symptoms more effectively and improve the person’s quality of life.
Geographical Landscape
North America is home to leading pharmaceutical companies, biotechnology firms, and academic research institutions that are actively engaged in developing new therapies, diagnostic tools, and disease-modifying treatments for Parkinson’s disease. North America has a significant aging population, with a large proportion of individuals aged 65 and older. As PD is more common in older adults, this demographic trend contributes to the prevalence of the disease in the region. The regulatory landscape in North America, particularly in the United States and Canada, plays a crucial role in shaping the market for PD diagnosis and treatment. Approval processes for new drugs, medical devices, and treatment modalities impact market entry and commercialization strategies.
The Asia-Pacific region is home to a diverse population, including both rapidly aging populations in countries like Japan and South Korea and younger populations in countries like India and Indonesia. The increasing prevalence of Parkinson’s disease, particularly in aging populations, drives demand for diagnosis and treatment options. Research and development activities in Parkinson’s disease diagnosis and treatment are gaining traction in the Asia-Pacific region, with academic institutions, healthcare organizations, and pharmaceutical companies collaborating to address unmet medical needs and develop innovative solutions.
Competitive Landscape
The competitive landscape for Parkinson’s disease diagnosis and treatment market is like a race among different companies. Each company tries to offer the best products and services to attract patients and healthcare providers. They compete by developing new medications, diagnostic tools, and treatment methods. Some companies may focus on affordability, while others emphasize innovation. It’s a dynamic environment where companies strive to stay ahead by offering effective solutions and staying up-to-date with advancements in the field.
Recent Developments
- In March 2022, Vyant Bio, Inc., a pioneering biotech firm dedicated to revolutionizing drug discovery for challenging neurological conditions, partnered with OrganoTherapeutics, a company specializing in personalized organoids mimicking Parkinson’s Disease (PD) symptoms, to collaborate on accelerating drug discovery efforts for treating PD.
- In May 2020, Kynmobi, developed by Sunovion Pharmaceuticals Inc., received approval from the U.S. FDA for the treatment of off-episodes in individuals with Parkinson’s Disease (PD).
- In January 2022, BlueRock Therapeutics initiated the initial administration of DA01 (dopaminergic neurons) to individuals with advanced Parkinson’s Disease (PD) in Canada. The expected successful conclusion of the trial and subsequent approval of the product are projected to stimulate growth in the region in the upcoming forecast period.
Parkinson’s Disease Diagnosis and Treatment Market Companies
- Siemens Healthineers AG
- Abbott Laboratories
- General Electric Company
- AbbVie
- Merck & Co.
- Pfizer
- Teva Pharmaceutical Industries Ltd.
- Sun Pharma
- Novartis AG
- Cerevel Therapeutics
Parkinson’s Disease Diagnosis and Treatment Market Segments
By Diagnosis
- Imaging Tests
- Blood Tests
- Other Tests
By Treatment
- Medications
- Carbidopa-levodopa
- Dopamine Agonists
- MAO-B Inhibitors
- COMT Inhibitors
- Anticholinergics
- Others
- Deep Brain Stimulation
- Other Treatments
By Geography
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- South America
Explore in-depth : https://www.healthcarewebwire.com/us-home-infusion-therapy-news/
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/parkinsons-disease-diagnosis-and-treatment-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5142
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
